Fox Run Management’s Ionis Pharmaceuticals IONS Stock Holding History

Fox Run Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,988	Closed	-$434K	–	1070
2025 Q2	$434K	Buy	+10,988	New	+$360K	0.07%	522
2024 Q3	–	Sell	-5,421	Closed	-$258K	–	944
2024 Q2	$258K	Buy	+5,421	New	+$222K	0.05%	593
2024 Q1	–	Sell	-9,271	Closed	-$469K	–	922
2023 Q4	$469K	Buy	+9,271	New	+$444K	0.12%	331
2022 Q3	–	Sell	-15,947	Closed	-$590K	–	718
2022 Q2	$590K	Buy	15,947 +6,893	+76%	+$260K	0.29%	84
2022 Q1	$335K	Buy	9,054 +1,730	+24%	+$56.6K	0.19%	230
2021 Q4	$223K	Sell	7,324 -17	-0.2%	-$535	0.13%	331
2021 Q3	$246K	Buy	+7,341	New	+$277K	0.15%	299
2018 Q1	–	Sell	-8,250	Closed	-$415K	–	809
2017 Q4	$415K	Buy	8,250 +2,450	+42%	+$134K	0.12%	349
2017 Q3	$294K	Buy	+5,800	New	+$304K	0.08%	502

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's IONS Position: Q3 2025 in Review

Fox Run Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2025, closing a stake of 10,988 shares — an estimated $434K sold.

Fox Run Management first reported a position in IONS in Q3 2017 and held it in 9 quarters. The position peaked at $590K in Q2 2022. 435 funds tracked by Wall St. Rank hold IONS as of Q3 2025.

Fox Run Management reported no remaining Ionis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Fox Run Management sold 10,988 Ionis Pharmaceuticals shares in Q3 2025, an estimated $434K.
Fox Run Management first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 9 quarters.
Fox Run Management's Ionis Pharmaceuticals position peaked at $590K in Q2 2022.
435 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.